nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—melanoma	0.376	1	CbGaD
Dihydroergotamine—CYP3A4—Temozolomide—melanoma	0.0817	0.376	CbGbCtD
Dihydroergotamine—ABCB1—Dactinomycin—melanoma	0.0496	0.229	CbGbCtD
Dihydroergotamine—CYP3A4—Vemurafenib—melanoma	0.0448	0.206	CbGbCtD
Dihydroergotamine—HTR1D—meninx—melanoma	0.0267	0.587	CbGeAlD
Dihydroergotamine—ABCB1—Docetaxel—melanoma	0.0256	0.118	CbGbCtD
Dihydroergotamine—CYP3A4—Docetaxel—melanoma	0.0154	0.0707	CbGbCtD
Dihydroergotamine—HTR1B—blood vessel—melanoma	0.00313	0.0688	CbGeAlD
Dihydroergotamine—HTR1D—blood vessel—melanoma	0.00303	0.0666	CbGeAlD
Dihydroergotamine—Lacrimal disorder—Docetaxel—melanoma	0.00245	0.0106	CcSEcCtD
Dihydroergotamine—Influenza-like symptoms—Temozolomide—melanoma	0.0023	0.01	CcSEcCtD
Dihydroergotamine—Stupor—Carmustine—melanoma	0.00228	0.0099	CcSEcCtD
Dihydroergotamine—Rigors—Temozolomide—melanoma	0.00201	0.00875	CcSEcCtD
Dihydroergotamine—Petechiae—Temozolomide—melanoma	0.002	0.00868	CcSEcCtD
Dihydroergotamine—Speech disorder—Carmustine—melanoma	0.00198	0.00859	CcSEcCtD
Dihydroergotamine—Speech disorder—Temozolomide—melanoma	0.00191	0.0083	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Bleomycin—melanoma	0.0019	0.00827	CcSEcCtD
Dihydroergotamine—Disturbance in attention—Temozolomide—melanoma	0.0019	0.00824	CcSEcCtD
Dihydroergotamine—Cystitis—Bleomycin—melanoma	0.00188	0.00818	CcSEcCtD
Dihydroergotamine—Herpes simplex—Temozolomide—melanoma	0.00178	0.00775	CcSEcCtD
Dihydroergotamine—Bladder pain—Bleomycin—melanoma	0.00176	0.00766	CcSEcCtD
Dihydroergotamine—Gait disturbance—Carmustine—melanoma	0.00174	0.00757	CcSEcCtD
Dihydroergotamine—Parosmia—Docetaxel—melanoma	0.00169	0.00732	CcSEcCtD
Dihydroergotamine—Gait disturbance—Temozolomide—melanoma	0.00169	0.00732	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Temozolomide—melanoma	0.00164	0.00714	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Carmustine—melanoma	0.00164	0.00714	CcSEcCtD
Dihydroergotamine—HTR1D—eye—melanoma	0.00161	0.0354	CbGeAlD
Dihydroergotamine—Influenza like illness—Temozolomide—melanoma	0.0016	0.00694	CcSEcCtD
Dihydroergotamine—Depressed level of consciousness—Temozolomide—melanoma	0.00159	0.0069	CcSEcCtD
Dihydroergotamine—HTR6—head—melanoma	0.00157	0.0345	CbGeAlD
Dihydroergotamine—Vaginal infection—Temozolomide—melanoma	0.00155	0.00674	CcSEcCtD
Dihydroergotamine—Injury—Bleomycin—melanoma	0.00154	0.00669	CcSEcCtD
Dihydroergotamine—Abnormal vision—Carmustine—melanoma	0.00148	0.00645	CcSEcCtD
Dihydroergotamine—Mental disability—Carmustine—melanoma	0.00148	0.00641	CcSEcCtD
Dihydroergotamine—Chills—Vemurafenib—melanoma	0.00145	0.0063	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Bleomycin—melanoma	0.00144	0.00627	CcSEcCtD
Dihydroergotamine—Abnormal vision—Temozolomide—melanoma	0.00143	0.00623	CcSEcCtD
Dihydroergotamine—Mental disability—Temozolomide—melanoma	0.00143	0.0062	CcSEcCtD
Dihydroergotamine—Swelling—Carmustine—melanoma	0.0014	0.00608	CcSEcCtD
Dihydroergotamine—Ear pain—Temozolomide—melanoma	0.0014	0.00608	CcSEcCtD
Dihydroergotamine—Eye pain—Carmustine—melanoma	0.00137	0.00594	CcSEcCtD
Dihydroergotamine—Myocardial ischaemia—Docetaxel—melanoma	0.00136	0.00591	CcSEcCtD
Dihydroergotamine—Injury—Carmustine—melanoma	0.00134	0.00584	CcSEcCtD
Dihydroergotamine—Rigors—Docetaxel—melanoma	0.00134	0.00582	CcSEcCtD
Dihydroergotamine—Eye pain—Temozolomide—melanoma	0.00132	0.00574	CcSEcCtD
Dihydroergotamine—HTR2B—skin of body—melanoma	0.0013	0.0287	CbGeAlD
Dihydroergotamine—Hot flush—Temozolomide—melanoma	0.00128	0.00554	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Temozolomide—melanoma	0.00127	0.00549	CcSEcCtD
Dihydroergotamine—Bronchospasm—Bleomycin—melanoma	0.0012	0.00523	CcSEcCtD
Dihydroergotamine—Myalgia—Vemurafenib—melanoma	0.0012	0.0052	CcSEcCtD
Dihydroergotamine—Arthralgia—Vemurafenib—melanoma	0.0012	0.0052	CcSEcCtD
Dihydroergotamine—Face oedema—Carmustine—melanoma	0.00119	0.00518	CcSEcCtD
Dihydroergotamine—Face oedema—Temozolomide—melanoma	0.00115	0.00501	CcSEcCtD
Dihydroergotamine—Dysphagia—Dactinomycin—melanoma	0.00114	0.00495	CcSEcCtD
Dihydroergotamine—Muscular weakness—Carmustine—melanoma	0.00109	0.00473	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Bleomycin—melanoma	0.00108	0.00467	CcSEcCtD
Dihydroergotamine—Hypotension—Vemurafenib—melanoma	0.00107	0.00466	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Bleomycin—melanoma	0.00107	0.00464	CcSEcCtD
Dihydroergotamine—Dysphagia—Carmustine—melanoma	0.00107	0.00464	CcSEcCtD
Dihydroergotamine—Influenza like illness—Docetaxel—melanoma	0.00106	0.00461	CcSEcCtD
Dihydroergotamine—Muscular weakness—Temozolomide—melanoma	0.00105	0.00457	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00105	0.00454	CcSEcCtD
Dihydroergotamine—Dysphagia—Temozolomide—melanoma	0.00103	0.00448	CcSEcCtD
Dihydroergotamine—Sweating increased—Temozolomide—melanoma	0.00101	0.00437	CcSEcCtD
Dihydroergotamine—Decreased appetite—Vemurafenib—melanoma	0.000998	0.00433	CcSEcCtD
Dihydroergotamine—Bronchitis—Temozolomide—melanoma	0.000992	0.00431	CcSEcCtD
Dihydroergotamine—Fatigue—Vemurafenib—melanoma	0.00099	0.0043	CcSEcCtD
Dihydroergotamine—ABCB1—blood vessel—melanoma	0.000986	0.0217	CbGeAlD
Dihydroergotamine—Hypoaesthesia—Bleomycin—melanoma	0.000974	0.00423	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Temozolomide—melanoma	0.000959	0.00416	CcSEcCtD
Dihydroergotamine—Pollakiuria—Temozolomide—melanoma	0.000953	0.00414	CcSEcCtD
Dihydroergotamine—HTR1B—head—melanoma	0.000945	0.0208	CbGeAlD
Dihydroergotamine—HTR1D—head—melanoma	0.000915	0.0201	CbGeAlD
Dihydroergotamine—Flushing—Bleomycin—melanoma	0.000909	0.00395	CcSEcCtD
Dihydroergotamine—Body temperature increased—Vemurafenib—melanoma	0.000908	0.00394	CcSEcCtD
Dihydroergotamine—Pharyngitis—Dactinomycin—melanoma	0.000906	0.00394	CcSEcCtD
Dihydroergotamine—Swelling—Docetaxel—melanoma	0.0009	0.00391	CcSEcCtD
Dihydroergotamine—Chills—Bleomycin—melanoma	0.000879	0.00382	CcSEcCtD
Dihydroergotamine—Sinusitis—Temozolomide—melanoma	0.000863	0.00375	CcSEcCtD
Dihydroergotamine—HTR2B—head—melanoma	0.000851	0.0187	CbGeAlD
Dihydroergotamine—Hypoaesthesia—Carmustine—melanoma	0.00085	0.00369	CcSEcCtD
Dihydroergotamine—Hot flush—Docetaxel—melanoma	0.000849	0.00369	CcSEcCtD
Dihydroergotamine—Flushing—Dactinomycin—melanoma	0.000848	0.00368	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Vemurafenib—melanoma	0.000846	0.00367	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Docetaxel—melanoma	0.000841	0.00365	CcSEcCtD
Dihydroergotamine—Asthenia—Vemurafenib—melanoma	0.000824	0.00358	CcSEcCtD
Dihydroergotamine—Visual impairment—Carmustine—melanoma	0.000824	0.00358	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Temozolomide—melanoma	0.000822	0.00357	CcSEcCtD
Dihydroergotamine—Pharyngitis—Temozolomide—melanoma	0.00082	0.00356	CcSEcCtD
Dihydroergotamine—Chills—Dactinomycin—melanoma	0.000819	0.00356	CcSEcCtD
Dihydroergotamine—Pruritus—Vemurafenib—melanoma	0.000812	0.00353	CcSEcCtD
Dihydroergotamine—Visual impairment—Temozolomide—melanoma	0.000796	0.00346	CcSEcCtD
Dihydroergotamine—Flushing—Carmustine—melanoma	0.000793	0.00344	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Bleomycin—melanoma	0.000791	0.00343	CcSEcCtD
Dihydroergotamine—Diarrhoea—Vemurafenib—melanoma	0.000786	0.00341	CcSEcCtD
Dihydroergotamine—Migraine—Docetaxel—melanoma	0.000782	0.00339	CcSEcCtD
Dihydroergotamine—Tinnitus—Temozolomide—melanoma	0.00077	0.00334	CcSEcCtD
Dihydroergotamine—Malaise—Bleomycin—melanoma	0.000769	0.00334	CcSEcCtD
Dihydroergotamine—Flushing—Temozolomide—melanoma	0.000767	0.00333	CcSEcCtD
Dihydroergotamine—HTR1A—head—melanoma	0.000763	0.0168	CbGeAlD
Dihydroergotamine—Dizziness—Vemurafenib—melanoma	0.000759	0.0033	CcSEcCtD
Dihydroergotamine—ADRA2A—mammalian vulva—melanoma	0.000747	0.0164	CbGeAlD
Dihydroergotamine—Chills—Temozolomide—melanoma	0.000741	0.00322	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Dactinomycin—melanoma	0.000738	0.0032	CcSEcCtD
Dihydroergotamine—Vomiting—Vemurafenib—melanoma	0.00073	0.00317	CcSEcCtD
Dihydroergotamine—Myalgia—Bleomycin—melanoma	0.000726	0.00315	CcSEcCtD
Dihydroergotamine—Rash—Vemurafenib—melanoma	0.000724	0.00314	CcSEcCtD
Dihydroergotamine—Dermatitis—Vemurafenib—melanoma	0.000723	0.00314	CcSEcCtD
Dihydroergotamine—Headache—Vemurafenib—melanoma	0.000719	0.00312	CcSEcCtD
Dihydroergotamine—Discomfort—Bleomycin—melanoma	0.000717	0.00311	CcSEcCtD
Dihydroergotamine—Malaise—Dactinomycin—melanoma	0.000717	0.00311	CcSEcCtD
Dihydroergotamine—Cramp muscle—Docetaxel—melanoma	0.000715	0.0031	CcSEcCtD
Dihydroergotamine—Confusional state—Bleomycin—melanoma	0.000701	0.00305	CcSEcCtD
Dihydroergotamine—Tremor—Carmustine—melanoma	0.000697	0.00303	CcSEcCtD
Dihydroergotamine—Oedema—Bleomycin—melanoma	0.000696	0.00302	CcSEcCtD
Dihydroergotamine—Dysphagia—Docetaxel—melanoma	0.000686	0.00298	CcSEcCtD
Dihydroergotamine—Agitation—Carmustine—melanoma	0.000684	0.00297	CcSEcCtD
Dihydroergotamine—Nausea—Vemurafenib—melanoma	0.000682	0.00296	CcSEcCtD
Dihydroergotamine—Myalgia—Dactinomycin—melanoma	0.000677	0.00294	CcSEcCtD
Dihydroergotamine—Bronchospasm—Docetaxel—melanoma	0.000675	0.00293	CcSEcCtD
Dihydroergotamine—Tremor—Temozolomide—melanoma	0.000674	0.00293	CcSEcCtD
Dihydroergotamine—Discomfort—Dactinomycin—melanoma	0.000669	0.0029	CcSEcCtD
Dihydroergotamine—Angina pectoris—Docetaxel—melanoma	0.000669	0.0029	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Temozolomide—melanoma	0.000667	0.0029	CcSEcCtD
Dihydroergotamine—Anorexia—Bleomycin—melanoma	0.000663	0.00288	CcSEcCtD
Dihydroergotamine—Agitation—Temozolomide—melanoma	0.000661	0.00287	CcSEcCtD
Dihydroergotamine—Hypotension—Bleomycin—melanoma	0.00065	0.00282	CcSEcCtD
Dihydroergotamine—Oedema—Dactinomycin—melanoma	0.000649	0.00282	CcSEcCtD
Dihydroergotamine—Malaise—Temozolomide—melanoma	0.000648	0.00282	CcSEcCtD
Dihydroergotamine—Vertigo—Temozolomide—melanoma	0.000646	0.00281	CcSEcCtD
Dihydroergotamine—Hypertension—Carmustine—melanoma	0.000642	0.00279	CcSEcCtD
Dihydroergotamine—Palpitations—Temozolomide—melanoma	0.000635	0.00276	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000634	0.00275	CcSEcCtD
Dihydroergotamine—Myalgia—Carmustine—melanoma	0.000633	0.00275	CcSEcCtD
Dihydroergotamine—Anxiety—Carmustine—melanoma	0.000631	0.00274	CcSEcCtD
Dihydroergotamine—Paraesthesia—Bleomycin—melanoma	0.000625	0.00271	CcSEcCtD
Dihydroergotamine—Hypertension—Temozolomide—melanoma	0.000621	0.0027	CcSEcCtD
Dihydroergotamine—Dyspnoea—Bleomycin—melanoma	0.00062	0.00269	CcSEcCtD
Dihydroergotamine—Anorexia—Dactinomycin—melanoma	0.000618	0.00269	CcSEcCtD
Dihydroergotamine—Confusional state—Carmustine—melanoma	0.000612	0.00266	CcSEcCtD
Dihydroergotamine—Myalgia—Temozolomide—melanoma	0.000612	0.00266	CcSEcCtD
Dihydroergotamine—Arthralgia—Temozolomide—melanoma	0.000612	0.00266	CcSEcCtD
Dihydroergotamine—Anxiety—Temozolomide—melanoma	0.00061	0.00265	CcSEcCtD
Dihydroergotamine—Oedema—Carmustine—melanoma	0.000607	0.00264	CcSEcCtD
Dihydroergotamine—Discomfort—Temozolomide—melanoma	0.000605	0.00263	CcSEcCtD
Dihydroergotamine—Decreased appetite—Bleomycin—melanoma	0.000605	0.00263	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Docetaxel—melanoma	0.000603	0.00262	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Docetaxel—melanoma	0.0006	0.0026	CcSEcCtD
Dihydroergotamine—Dry mouth—Temozolomide—melanoma	0.000599	0.0026	CcSEcCtD
Dihydroergotamine—HTR2B—lymph node—melanoma	0.000596	0.0131	CbGeAlD
Dihydroergotamine—Pain—Bleomycin—melanoma	0.000595	0.00258	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Docetaxel—melanoma	0.000595	0.00258	CcSEcCtD
Dihydroergotamine—Tachycardia—Carmustine—melanoma	0.000593	0.00257	CcSEcCtD
Dihydroergotamine—Confusional state—Temozolomide—melanoma	0.000592	0.00257	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000591	0.00257	CcSEcCtD
Dihydroergotamine—Oedema—Temozolomide—melanoma	0.000587	0.00255	CcSEcCtD
Dihydroergotamine—Anorexia—Carmustine—melanoma	0.000579	0.00251	CcSEcCtD
Dihydroergotamine—Epistaxis—Docetaxel—melanoma	0.000577	0.00251	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Bleomycin—melanoma	0.000573	0.00249	CcSEcCtD
Dihydroergotamine—Hypotension—Carmustine—melanoma	0.000567	0.00246	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Temozolomide—melanoma	0.000567	0.00246	CcSEcCtD
Dihydroergotamine—Decreased appetite—Dactinomycin—melanoma	0.000564	0.00245	CcSEcCtD
Dihydroergotamine—Fatigue—Dactinomycin—melanoma	0.000559	0.00243	CcSEcCtD
Dihydroergotamine—Anorexia—Temozolomide—melanoma	0.000559	0.00243	CcSEcCtD
Dihydroergotamine—Pain—Dactinomycin—melanoma	0.000555	0.00241	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Carmustine—melanoma	0.000553	0.0024	CcSEcCtD
Dihydroergotamine—Urticaria—Bleomycin—melanoma	0.000553	0.0024	CcSEcCtD
Dihydroergotamine—Rhinitis—Docetaxel—melanoma	0.000551	0.00239	CcSEcCtD
Dihydroergotamine—Body temperature increased—Bleomycin—melanoma	0.00055	0.00239	CcSEcCtD
Dihydroergotamine—Insomnia—Carmustine—melanoma	0.000549	0.00239	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Docetaxel—melanoma	0.000547	0.00237	CcSEcCtD
Dihydroergotamine—Paraesthesia—Carmustine—melanoma	0.000545	0.00237	CcSEcCtD
Dihydroergotamine—Pharyngitis—Docetaxel—melanoma	0.000545	0.00237	CcSEcCtD
Dihydroergotamine—Dyspnoea—Carmustine—melanoma	0.000541	0.00235	CcSEcCtD
Dihydroergotamine—Somnolence—Carmustine—melanoma	0.00054	0.00234	CcSEcCtD
Dihydroergotamine—ADRA2A—head—melanoma	0.000535	0.0118	CbGeAlD
Dihydroergotamine—Feeling abnormal—Dactinomycin—melanoma	0.000535	0.00232	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Temozolomide—melanoma	0.000535	0.00232	CcSEcCtD
Dihydroergotamine—Insomnia—Temozolomide—melanoma	0.000531	0.0023	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Dactinomycin—melanoma	0.000531	0.0023	CcSEcCtD
Dihydroergotamine—Visual impairment—Docetaxel—melanoma	0.000529	0.0023	CcSEcCtD
Dihydroergotamine—Decreased appetite—Carmustine—melanoma	0.000528	0.00229	CcSEcCtD
Dihydroergotamine—Paraesthesia—Temozolomide—melanoma	0.000527	0.00229	CcSEcCtD
Dihydroergotamine—Dyspnoea—Temozolomide—melanoma	0.000523	0.00227	CcSEcCtD
Dihydroergotamine—Somnolence—Temozolomide—melanoma	0.000522	0.00227	CcSEcCtD
Dihydroergotamine—ABCB1—retina—melanoma	0.00052	0.0114	CbGeAlD
Dihydroergotamine—Pain—Carmustine—melanoma	0.000519	0.00226	CcSEcCtD
Dihydroergotamine—Dyspepsia—Temozolomide—melanoma	0.000517	0.00224	CcSEcCtD
Dihydroergotamine—Body temperature increased—Dactinomycin—melanoma	0.000513	0.00223	CcSEcCtD
Dihydroergotamine—Abdominal pain—Dactinomycin—melanoma	0.000513	0.00223	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Bleomycin—melanoma	0.000513	0.00223	CcSEcCtD
Dihydroergotamine—Decreased appetite—Temozolomide—melanoma	0.00051	0.00222	CcSEcCtD
Dihydroergotamine—Flushing—Docetaxel—melanoma	0.00051	0.00221	CcSEcCtD
Dihydroergotamine—Fatigue—Temozolomide—melanoma	0.000506	0.0022	CcSEcCtD
Dihydroergotamine—Pain—Temozolomide—melanoma	0.000502	0.00218	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Carmustine—melanoma	0.0005	0.00217	CcSEcCtD
Dihydroergotamine—Asthenia—Bleomycin—melanoma	0.000499	0.00217	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Carmustine—melanoma	0.000497	0.00216	CcSEcCtD
Dihydroergotamine—Chills—Docetaxel—melanoma	0.000493	0.00214	CcSEcCtD
Dihydroergotamine—Pruritus—Bleomycin—melanoma	0.000492	0.00214	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Temozolomide—melanoma	0.000484	0.0021	CcSEcCtD
Dihydroergotamine—Abdominal pain—Carmustine—melanoma	0.00048	0.00208	CcSEcCtD
Dihydroergotamine—Body temperature increased—Carmustine—melanoma	0.00048	0.00208	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Temozolomide—melanoma	0.00048	0.00208	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Dactinomycin—melanoma	0.000478	0.00208	CcSEcCtD
Dihydroergotamine—Urticaria—Temozolomide—melanoma	0.000466	0.00202	CcSEcCtD
Dihydroergotamine—Asthenia—Dactinomycin—melanoma	0.000466	0.00202	CcSEcCtD
Dihydroergotamine—Abdominal pain—Temozolomide—melanoma	0.000464	0.00201	CcSEcCtD
Dihydroergotamine—Body temperature increased—Temozolomide—melanoma	0.000464	0.00201	CcSEcCtD
Dihydroergotamine—Muscle spasms—Docetaxel—melanoma	0.00046	0.002	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Carmustine—melanoma	0.000447	0.00194	CcSEcCtD
Dihydroergotamine—Diarrhoea—Dactinomycin—melanoma	0.000444	0.00193	CcSEcCtD
Dihydroergotamine—Vomiting—Bleomycin—melanoma	0.000442	0.00192	CcSEcCtD
Dihydroergotamine—Rash—Bleomycin—melanoma	0.000439	0.0019	CcSEcCtD
Dihydroergotamine—Dermatitis—Bleomycin—melanoma	0.000438	0.0019	CcSEcCtD
Dihydroergotamine—Asthenia—Carmustine—melanoma	0.000436	0.00189	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Temozolomide—melanoma	0.000432	0.00188	CcSEcCtD
Dihydroergotamine—Palpitations—Docetaxel—melanoma	0.000423	0.00183	CcSEcCtD
Dihydroergotamine—Asthenia—Temozolomide—melanoma	0.000421	0.00183	CcSEcCtD
Dihydroergotamine—ABCB1—mammalian vulva—melanoma	0.000416	0.00915	CbGeAlD
Dihydroergotamine—Diarrhoea—Carmustine—melanoma	0.000415	0.0018	CcSEcCtD
Dihydroergotamine—Pruritus—Temozolomide—melanoma	0.000415	0.0018	CcSEcCtD
Dihydroergotamine—Nausea—Bleomycin—melanoma	0.000413	0.00179	CcSEcCtD
Dihydroergotamine—Hypertension—Docetaxel—melanoma	0.000413	0.00179	CcSEcCtD
Dihydroergotamine—Vomiting—Dactinomycin—melanoma	0.000413	0.00179	CcSEcCtD
Dihydroergotamine—Rash—Dactinomycin—melanoma	0.000409	0.00178	CcSEcCtD
Dihydroergotamine—Arthralgia—Docetaxel—melanoma	0.000407	0.00177	CcSEcCtD
Dihydroergotamine—Myalgia—Docetaxel—melanoma	0.000407	0.00177	CcSEcCtD
Dihydroergotamine—Dizziness—Carmustine—melanoma	0.000402	0.00174	CcSEcCtD
Dihydroergotamine—Diarrhoea—Temozolomide—melanoma	0.000402	0.00174	CcSEcCtD
Dihydroergotamine—Dry mouth—Docetaxel—melanoma	0.000398	0.00173	CcSEcCtD
Dihydroergotamine—Confusional state—Docetaxel—melanoma	0.000394	0.00171	CcSEcCtD
Dihydroergotamine—Oedema—Docetaxel—melanoma	0.00039	0.00169	CcSEcCtD
Dihydroergotamine—Dizziness—Temozolomide—melanoma	0.000388	0.00169	CcSEcCtD
Dihydroergotamine—Vomiting—Carmustine—melanoma	0.000386	0.00168	CcSEcCtD
Dihydroergotamine—Nausea—Dactinomycin—melanoma	0.000385	0.00167	CcSEcCtD
Dihydroergotamine—Shock—Docetaxel—melanoma	0.000384	0.00167	CcSEcCtD
Dihydroergotamine—Rash—Carmustine—melanoma	0.000383	0.00166	CcSEcCtD
Dihydroergotamine—Dermatitis—Carmustine—melanoma	0.000383	0.00166	CcSEcCtD
Dihydroergotamine—Tachycardia—Docetaxel—melanoma	0.000381	0.00165	CcSEcCtD
Dihydroergotamine—Headache—Carmustine—melanoma	0.00038	0.00165	CcSEcCtD
Dihydroergotamine—ADRA2A—lymph node—melanoma	0.000374	0.00823	CbGeAlD
Dihydroergotamine—Vomiting—Temozolomide—melanoma	0.000373	0.00162	CcSEcCtD
Dihydroergotamine—Anorexia—Docetaxel—melanoma	0.000372	0.00162	CcSEcCtD
Dihydroergotamine—Rash—Temozolomide—melanoma	0.00037	0.00161	CcSEcCtD
Dihydroergotamine—Dermatitis—Temozolomide—melanoma	0.00037	0.00161	CcSEcCtD
Dihydroergotamine—Headache—Temozolomide—melanoma	0.000368	0.0016	CcSEcCtD
Dihydroergotamine—Hypotension—Docetaxel—melanoma	0.000365	0.00158	CcSEcCtD
Dihydroergotamine—Nausea—Carmustine—melanoma	0.000361	0.00157	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Docetaxel—melanoma	0.000356	0.00154	CcSEcCtD
Dihydroergotamine—Insomnia—Docetaxel—melanoma	0.000353	0.00153	CcSEcCtD
Dihydroergotamine—Paraesthesia—Docetaxel—melanoma	0.00035	0.00152	CcSEcCtD
Dihydroergotamine—Nausea—Temozolomide—melanoma	0.000349	0.00151	CcSEcCtD
Dihydroergotamine—Dyspnoea—Docetaxel—melanoma	0.000348	0.00151	CcSEcCtD
Dihydroergotamine—Somnolence—Docetaxel—melanoma	0.000347	0.00151	CcSEcCtD
Dihydroergotamine—Dyspepsia—Docetaxel—melanoma	0.000344	0.00149	CcSEcCtD
Dihydroergotamine—Decreased appetite—Docetaxel—melanoma	0.000339	0.00147	CcSEcCtD
Dihydroergotamine—Fatigue—Docetaxel—melanoma	0.000336	0.00146	CcSEcCtD
Dihydroergotamine—Pain—Docetaxel—melanoma	0.000334	0.00145	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Docetaxel—melanoma	0.000322	0.0014	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Docetaxel—melanoma	0.000319	0.00139	CcSEcCtD
Dihydroergotamine—Abdominal pain—Docetaxel—melanoma	0.000309	0.00134	CcSEcCtD
Dihydroergotamine—Body temperature increased—Docetaxel—melanoma	0.000309	0.00134	CcSEcCtD
Dihydroergotamine—ABCB1—head—melanoma	0.000298	0.00655	CbGeAlD
Dihydroergotamine—Hypersensitivity—Docetaxel—melanoma	0.000288	0.00125	CcSEcCtD
Dihydroergotamine—Asthenia—Docetaxel—melanoma	0.00028	0.00122	CcSEcCtD
Dihydroergotamine—Pruritus—Docetaxel—melanoma	0.000276	0.0012	CcSEcCtD
Dihydroergotamine—Diarrhoea—Docetaxel—melanoma	0.000267	0.00116	CcSEcCtD
Dihydroergotamine—Dizziness—Docetaxel—melanoma	0.000258	0.00112	CcSEcCtD
Dihydroergotamine—Vomiting—Docetaxel—melanoma	0.000248	0.00108	CcSEcCtD
Dihydroergotamine—Rash—Docetaxel—melanoma	0.000246	0.00107	CcSEcCtD
Dihydroergotamine—Dermatitis—Docetaxel—melanoma	0.000246	0.00107	CcSEcCtD
Dihydroergotamine—Headache—Docetaxel—melanoma	0.000244	0.00106	CcSEcCtD
Dihydroergotamine—Nausea—Docetaxel—melanoma	0.000232	0.00101	CcSEcCtD
Dihydroergotamine—ABCB1—lymph node—melanoma	0.000209	0.00458	CbGeAlD
Dihydroergotamine—HTR6—Signaling by GPCR—HRAS—melanoma	1.38e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL8—melanoma	1.38e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SPP1—melanoma	1.38e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAP2K2—melanoma	1.37e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HRAS—melanoma	1.37e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL8—melanoma	1.37e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PIK3CA—melanoma	1.36e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1B—melanoma	1.36e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MDM2—melanoma	1.36e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL8—melanoma	1.35e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1B—melanoma	1.35e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—melanoma	1.34e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HRAS—melanoma	1.34e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—MAPK3—melanoma	1.34e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ERBB2—melanoma	1.34e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—melanoma	1.33e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—melanoma	1.33e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL2—melanoma	1.33e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—VCAN—melanoma	1.33e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—melanoma	1.32e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CB—melanoma	1.32e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—melanoma	1.32e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1B—melanoma	1.32e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—melanoma	1.32e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BRAF—melanoma	1.31e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—melanoma	1.31e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—melanoma	1.31e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—melanoma	1.31e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—melanoma	1.31e-05	0.0001	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—melanoma	1.3e-05	9.99e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RAC1—melanoma	1.3e-05	9.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—melanoma	1.3e-05	9.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—melanoma	1.29e-05	9.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—melanoma	1.29e-05	9.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—melanoma	1.29e-05	9.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—melanoma	1.29e-05	9.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CTNNB1—melanoma	1.28e-05	9.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—melanoma	1.28e-05	9.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—MAPK1—melanoma	1.27e-05	9.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—melanoma	1.27e-05	9.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CTNNB1—melanoma	1.27e-05	9.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—melanoma	1.27e-05	9.72e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—melanoma	1.27e-05	9.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRAS—melanoma	1.26e-05	9.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—melanoma	1.26e-05	9.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—melanoma	1.26e-05	9.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDKN1A—melanoma	1.25e-05	9.6e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTEN—melanoma	1.25e-05	9.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—melanoma	1.25e-05	9.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—melanoma	1.25e-05	9.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CTNNB1—melanoma	1.25e-05	9.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NFKB1—melanoma	1.24e-05	9.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDKN1A—melanoma	1.24e-05	9.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTEN—melanoma	1.24e-05	9.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1B—melanoma	1.24e-05	9.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAP2K1—melanoma	1.24e-05	9.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—melanoma	1.24e-05	9.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NFKB1—melanoma	1.24e-05	9.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CD—melanoma	1.23e-05	9.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—melanoma	1.23e-05	9.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—melanoma	1.22e-05	9.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—melanoma	1.22e-05	9.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDKN1A—melanoma	1.22e-05	9.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—melanoma	1.22e-05	9.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTEN—melanoma	1.22e-05	9.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—melanoma	1.22e-05	9.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—melanoma	1.21e-05	9.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—melanoma	1.21e-05	9.27e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NFKB1—melanoma	1.21e-05	9.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—melanoma	1.21e-05	9.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—melanoma	1.2e-05	9.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—melanoma	1.19e-05	9.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—melanoma	1.19e-05	9.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—melanoma	1.18e-05	9.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGF2—melanoma	1.18e-05	9.01e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CTNNB1—melanoma	1.17e-05	8.97e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PRKCA—melanoma	1.16e-05	8.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CD—melanoma	1.16e-05	8.85e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ERCC2—melanoma	1.15e-05	8.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—melanoma	1.15e-05	8.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FN1—melanoma	1.15e-05	8.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDKN1A—melanoma	1.14e-05	8.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTEN—melanoma	1.14e-05	8.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—melanoma	1.14e-05	8.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NFKB1—melanoma	1.14e-05	8.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—melanoma	1.13e-05	8.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH1—melanoma	1.12e-05	8.6e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—melanoma	1.12e-05	8.58e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP17A1—melanoma	1.12e-05	8.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—melanoma	1.12e-05	8.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NRAS—melanoma	1.12e-05	8.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—melanoma	1.11e-05	8.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—melanoma	1.11e-05	8.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NRAS—melanoma	1.11e-05	8.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—melanoma	1.11e-05	8.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MDM2—melanoma	1.1e-05	8.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CD80—melanoma	1.1e-05	8.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KIT—melanoma	1.1e-05	8.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—melanoma	1.1e-05	8.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APC—melanoma	1.1e-05	8.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—NRAS—melanoma	1.1e-05	8.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—melanoma	1.1e-05	8.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—melanoma	1.09e-05	8.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGF—melanoma	1.09e-05	8.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ERBB2—melanoma	1.09e-05	8.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NRAS—melanoma	1.08e-05	8.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CB—melanoma	1.07e-05	8.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK3—melanoma	1.07e-05	8.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK3—melanoma	1.06e-05	8.12e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GNA11—melanoma	1.06e-05	8.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK3—melanoma	1.05e-05	8.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—melanoma	1.04e-05	7.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK3—melanoma	1.04e-05	7.95e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—FASN—melanoma	1.04e-05	7.93e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BRAF—melanoma	1.03e-05	7.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—melanoma	1.03e-05	7.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—melanoma	1.03e-05	7.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—melanoma	1.03e-05	7.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRAS—melanoma	1.02e-05	7.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—melanoma	1.02e-05	7.82e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC5A5—melanoma	1.02e-05	7.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NRAS—melanoma	1.02e-05	7.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK1—melanoma	1.02e-05	7.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—melanoma	1.02e-05	7.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—melanoma	1.01e-05	7.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK1—melanoma	1.01e-05	7.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—melanoma	1.01e-05	7.72e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CB—melanoma	1.01e-05	7.71e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—melanoma	1.01e-05	7.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1B—melanoma	1.01e-05	7.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK1—melanoma	1e-05	7.67e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—melanoma	1e-05	7.66e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—melanoma	9.98e-06	7.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—melanoma	9.95e-06	7.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK1—melanoma	9.88e-06	7.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—melanoma	9.88e-06	7.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—melanoma	9.85e-06	7.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—melanoma	9.84e-06	7.53e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GNAQ—melanoma	9.84e-06	7.53e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CD44—melanoma	9.84e-06	7.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—melanoma	9.79e-06	7.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK3—melanoma	9.75e-06	7.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAP2K1—melanoma	9.72e-06	7.45e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CD—melanoma	9.66e-06	7.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—melanoma	9.6e-06	7.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—melanoma	9.59e-06	7.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	9.57e-06	7.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—melanoma	9.53e-06	7.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CTNNB1—melanoma	9.5e-06	7.27e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—melanoma	9.49e-06	7.26e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—melanoma	9.46e-06	7.24e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP1B1—melanoma	9.43e-06	7.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—melanoma	9.33e-06	7.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—melanoma	9.31e-06	7.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK1—melanoma	9.28e-06	7.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—melanoma	9.28e-06	7.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDKN1A—melanoma	9.28e-06	7.1e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTEN—melanoma	9.26e-06	7.09e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF2—melanoma	9.25e-06	7.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NFKB1—melanoma	9.21e-06	7.05e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—melanoma	9.09e-06	6.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—melanoma	9.03e-06	6.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—melanoma	8.82e-06	6.75e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—melanoma	8.77e-06	6.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—melanoma	8.77e-06	6.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—melanoma	8.76e-06	6.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTEN—melanoma	8.7e-06	6.66e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	8.69e-06	6.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MDM2—melanoma	8.65e-06	6.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—melanoma	8.57e-06	6.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—melanoma	8.54e-06	6.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ERBB2—melanoma	8.53e-06	6.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—melanoma	8.47e-06	6.48e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	8.42e-06	6.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—melanoma	8.36e-06	6.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—melanoma	8.29e-06	6.35e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—melanoma	8.28e-06	6.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NRAS—melanoma	8.26e-06	6.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRAS—melanoma	8.16e-06	6.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRAS—melanoma	8.1e-06	6.2e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—melanoma	8.09e-06	6.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—melanoma	8.05e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRAS—melanoma	8.04e-06	6.15e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CD—melanoma	7.99e-06	6.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRAS—melanoma	7.93e-06	6.07e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK3—melanoma	7.91e-06	6.06e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	7.9e-06	6.05e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—melanoma	7.89e-06	6.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	7.82e-06	5.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—melanoma	7.81e-06	5.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—melanoma	7.79e-06	5.96e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCB1—melanoma	7.77e-06	5.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—melanoma	7.75e-06	5.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—melanoma	7.74e-06	5.93e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—melanoma	7.73e-06	5.92e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—melanoma	7.69e-06	5.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—melanoma	7.69e-06	5.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—melanoma	7.59e-06	5.81e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—melanoma	7.54e-06	5.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK1—melanoma	7.53e-06	5.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—melanoma	7.52e-06	5.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	7.47e-06	5.72e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRAS—melanoma	7.45e-06	5.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—melanoma	7.32e-06	5.6e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	7.29e-06	5.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTEN—melanoma	7.28e-06	5.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NFKB1—melanoma	7.24e-06	5.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—melanoma	7.21e-06	5.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—melanoma	7.15e-06	5.48e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PRKCA—melanoma	7.15e-06	5.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—melanoma	7.13e-06	5.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—melanoma	7.11e-06	5.44e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—melanoma	7.1e-06	5.43e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ERCC2—melanoma	7.09e-06	5.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—melanoma	7e-06	5.36e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CB—melanoma	6.96e-06	5.33e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—melanoma	6.9e-06	5.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—melanoma	6.58e-06	5.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—melanoma	6.57e-06	5.03e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—melanoma	6.53e-06	5e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—melanoma	6.51e-06	4.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRAS—melanoma	6.49e-06	4.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—melanoma	6.32e-06	4.84e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK3—melanoma	6.22e-06	4.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—melanoma	6.14e-06	4.7e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—melanoma	6.05e-06	4.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRAS—melanoma	6.04e-06	4.63e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTEN—melanoma	6.02e-06	4.61e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK1—melanoma	5.92e-06	4.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—melanoma	5.91e-06	4.53e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—melanoma	5.78e-06	4.43e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—melanoma	5.6e-06	4.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—melanoma	5.59e-06	4.28e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—melanoma	5.4e-06	4.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—melanoma	5.34e-06	4.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	5.13e-06	3.93e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—melanoma	5.01e-06	3.84e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—melanoma	4.97e-06	3.8e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CD—melanoma	4.92e-06	3.77e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—melanoma	4.86e-06	3.72e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRAS—melanoma	4.75e-06	3.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—melanoma	4.55e-06	3.48e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CB—melanoma	4.29e-06	3.28e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—melanoma	4.25e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—melanoma	4.24e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—melanoma	4.19e-06	3.21e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTEN—melanoma	3.71e-06	2.84e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—melanoma	3.47e-06	2.65e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—melanoma	2.62e-06	2e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—melanoma	2.14e-06	1.64e-05	CbGpPWpGaD
